Report Description

Global Head and Neck Cancer Therapeutics Market stood at USD2024.33 million in 2021 and is expected to grow at an impressive rate of 7.22% during the forecast period. This can be ascribed to the growing popularity of precision medicine and the need for new therapies for the treatment of different types of head and neck cancers. Furthermore, growing consumption of tobacco and alcohol is further contributing to the increasing incidences of head and neck cancers. According to World Health Organization, Tobacco kills nearly half of its users, accounting for around 8 million deaths every year. Out of which, 7 million deaths are caused due to direct tobacco use, while the remaining is caused due to the exposure of nonsmokers to passive smoking.

Increasing Number of Clinical Trials

The increasing research & development activities related to the development of different types of therapies related to head and neck cancer has significantly augmented the number of clinical trials related to the same. There are around 2957 clinical trials launched on head and neck cancer till date. In 2021, around 52 clinical trials were launched globally related to head and neck cancer. This count is expected to increase in the coming years, thereby supporting the market growth in the coming years.

Growing Adoption of New Treatments

Development of immunotherapies, CAR-T cell therapies, among others for the treatment of different types of cancer is expected to drive the growth of head and neck cancer therapeutics market. Several clinical trials related to immunotherapies and targeted therapies are going on. In the forecast period, several advanced therapies can be expected to treat head and neck cancer.

Increasing Number of Players

Many healthcare players are either developing drugs or therapies for the treatment of head and neck cancer or collaborating with other companies who have developed the therapy or drug earlier. Some healthcare majors are simply acquiring the smaller ones and expanding their portfolio of head and neck cancer therapeutic solutions. This, in turn, is leading to a lot of investment in the head and neck cancer therapeutics industry. For instance, in January 2021, AbbVie, Inc. developed SkinMedica Neck Correct Cream, which focuses on the biology of the skin on the neck and decollete area.


DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The global head and neck cancer therapeutics market is segmented by type, diagnostic methods, treatment type, disease indication, route of administration, therapeutic class, end user, region, and company. Based on type, the global head and neck cancer therapeutics market can be split into diagnostic methods and treatment types. Diagnostics methods can be further categorized into Biopsy, Imaging, Endoscopy and Others. While treatment type can be further fragmented into Surgery, Radiation Therapy, Chemotherapy, Immunotherapy and Targeted Therapy. Disease indication segment can be fragmented into Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Nasopharyngeal Cancer, Salivary Gland Cancer and Hypopharyngeal Cancer. The Route of Administration can be split into Injectable and Oral. Therapeutic Class can be categorized as PD Inhibitors (PD-1 and PD-L1), EGFR Inhibitors and Microtubule Inhibitors. In terms of end user, the global head and neck cancer therapeutics market can be categorized as Hospitals, Specialty Clinics, Ambulatory Surgical Centers, And Others. Regionally, the Head and Neck Cancer Therapeutics Market can be categorized into North America, Asia Pacific, Europe, South America, and Middle East & Africa. North America dominates the overall Head and Neck Cancer Therapeutics Market with United States having the biggest market. The United States Head and Neck Cancer Therapeutics Market stood at USD562.21 million in 2021.

Major companies in the market are Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc., among others. Major players operating in the market are following strategies such as mergers and acquisitions, new therapy or drug launches, and others to stay competitive and have an edge over other players in the market.

Attribute

Details

Market Size Value in 2021

USD2024.33 million

Revenue Forecast in 2027

USD3126.26 million

United States Market Size Value in 2021

USD562.21 million

Growth Rate

7.22%

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Type

o   Diagnostic Methods

o   Treatment Type

§  Disease Indication

§  Route of Administration

§  Therapeutic Class

·         End User

Regional Scope

North America; Asia Pacific; Europe, South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; Germany; France; United Kingdom; Italy; Spain; China; India; Japan; Australia; South Korea; Singapore; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Key Companies Profiled

Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc.

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global Head and Neck Cancer Therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Head and Neck Cancer Therapeutics Market, By Type:
    • Diagnostic Methods
      • Biopsy
      • Imaging
      • Endoscopy
      • Others
    • Treatment Type
      • Surgery
      • Radiation Therapy
      • Chemotherapy
      • Immunotherapy
      • Targeted Therapy
  • Head and Neck Cancer Therapeutics Market, By Disease Indication:
    • Lip and Oral Cavity Cancer
    • Laryngeal Cancer
    • Oropharyngeal Cancer
    • Salivary Gland Cancer
    • Nasopharyngeal Cancer
    • Hypopharyngeal Cancer
  • Head and Neck Cancer Therapeutics Market, By Route of Administration:
    • Injectable
    • Oral
  • Head and Neck Cancer Therapeutics Market, By Therapeutic Class:
    • PD Inhibitors
    • EGFR Inhibitors
    • Microtubule Inhibitors
  • Head and Neck Cancer Therapeutics Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others
  • Head and Neck Cancer Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Singapore
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Head and Neck Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of content

1.    Product Overview

2.    Research Methodology

3.    Executive Summary

4.    Voice of Customer

4.1.  Brand Awareness

4.2.  Preferred Diagnostic Method

4.3.  Preferred Treatment Type

4.4.  Preferred Route of Administration

5.    Global Head and Neck Cancer Therapeutics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Type (Diagnostic Methods v/s Treatment Type)

5.2.1.1.         By Diagnostic Methods (Biopsy, Imaging, Endoscopy, Others)

5.2.1.2.         By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy)

5.2.1.2.1.             By Disease Indication (Lip and Oral Cavity Cancer, Laryngeal Cancer, Oropharyngeal Cancer, Salivary Gland Cancer, Nasopharyngeal Cancer, Hypopharyngeal Cancer)

5.2.1.2.2.             By Route of Administration (Injectable, Oral)

5.2.1.2.3.             By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors)

5.2.1.3.         By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)

5.2.2.     By Region

5.2.3.     By Company (2021)

5.3.  Product Market Map

6.    North America Head and Neck Cancer Therapeutics Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type

6.2.1.1.         By Diagnostic Methods

6.2.1.2.         By Treatment Type

6.2.1.2.1.             By Disease Indication

6.2.1.2.2.             By Route of Administration

6.2.1.2.3.             By Therapeutic Class

6.2.1.3.         By End User

6.2.2.     By Country

6.3.  North America: Country Analysis

6.3.1.     United States Head and Neck Cancer Therapeutics Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Type

6.3.1.2.1.1. By Diagnostic Methods

6.3.1.2.1.2. By Treatment Type

6.3.1.2.1.2.1.     By Disease Indication

6.3.1.2.1.2.2.     By Route of Administration

6.3.1.2.1.2.3.     By Therapeutic Class

6.3.1.2.2.             By End User

6.3.2.     Canada Head and Neck Cancer Therapeutics Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Type

6.3.2.2.1.1. By Diagnostic Methods

6.3.2.2.1.2. By Treatment Type

6.3.2.2.1.2.1.     By Disease Indication

6.3.2.2.1.2.2.     By Route of Administration

6.3.2.2.1.2.3.     By Therapeutic Class

6.3.2.2.2.             By End User

6.3.3.     Mexico Head and Neck Cancer Therapeutics Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Type

6.3.3.2.1.1. By Diagnostic Methods

6.3.3.2.1.2. By Treatment Type

6.3.3.2.1.2.1.     By Disease Indication

6.3.3.2.1.2.2.     By Route of Administration

6.3.3.2.1.2.3.     By Therapeutic Class

6.3.3.2.2.             By End User

7.    Europe Head and Neck Cancer Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.1.1.         By Diagnostic Methods

7.2.1.2.         By Treatment Type

7.2.1.2.1.             By Disease Indication

7.2.1.2.2.             By Route of Administration

7.2.1.2.3.             By Therapeutic Class

7.2.1.3.         By End User

7.2.2.     By Country

7.3.  Europe: Country Analysis

7.3.1.     France Head and Neck Cancer Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.1.1. By Diagnostic Methods

7.3.1.2.1.2. By Treatment Type

7.3.1.2.1.2.1.     By Disease Indication

7.3.1.2.1.2.2.     By Route of Administration

7.3.1.2.1.2.3.     By Therapeutic Class

7.3.1.2.2.             By End User

7.3.2.     Germany Head and Neck Cancer Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.1.1. By Diagnostic Methods

7.3.2.2.1.2. By Treatment Type

7.3.2.2.1.2.1.     By Disease Indication

7.3.2.2.1.2.2.     By Route of Administration

7.3.2.2.1.2.3.     By Therapeutic Class

7.3.2.2.2.             By End User

7.3.3.     United Kingdom Head and Neck Cancer Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.1.1. By Diagnostic Methods

7.3.3.2.1.2. By Treatment Type

7.3.3.2.1.2.1.     By Disease Indication

7.3.3.2.1.2.2.     By Route of Administration

7.3.3.2.1.2.3.     By Therapeutic Class

7.3.3.2.2.             By End User

7.3.4.     Italy Head and Neck Cancer Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Type

7.3.4.2.1.1. By Diagnostic Methods

7.3.4.2.1.2. By Treatment Type

7.3.4.2.1.2.1.     By Disease Indication

7.3.4.2.1.2.2.     By Route of Administration

7.3.4.2.1.2.3.     By Therapeutic Class

7.3.4.2.2.             By End User

7.3.5.     Spain Head and Neck Cancer Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Type

7.3.5.2.1.1. By Diagnostic Methods

7.3.5.2.1.2. By Treatment Type

7.3.5.2.1.2.1.     By Disease Indication

7.3.5.2.1.2.2.     By Route of Administration

7.3.5.2.1.2.3.     By Therapeutic Class

7.3.5.2.2.             By End User

8.    Asia Pacific Head and Neck Cancer Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.1.1.         By Diagnostic Methods

8.2.1.2.         By Treatment Type

8.2.1.2.1.             By Disease Indication

8.2.1.2.2.             By Route of Administration

8.2.1.2.3.             By Therapeutic Class

8.2.1.3.         By End User

8.2.2.     By Country

8.3.  Asia Pacific: Country Analysis

8.3.1.     China Head and Neck Cancer Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.1.1. By Diagnostic Methods

8.3.1.2.1.2. By Treatment Type

8.3.1.2.1.2.1.     By Disease Indication

8.3.1.2.1.2.2.     By Route of Administration

8.3.1.2.1.2.3.     By Therapeutic Class

8.3.1.2.2.             By End User

8.3.2.     India Head and Neck Cancer Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.1.1. By Diagnostic Methods

8.3.2.2.1.2. By Treatment Type

8.3.2.2.1.2.1.     By Disease Indication

8.3.2.2.1.2.2.     By Route of Administration

8.3.2.2.1.2.3.     By Therapeutic Class

8.3.2.2.2.             By End User

8.3.3.     Japan Head and Neck Cancer Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.1.1. By Diagnostic Methods

8.3.3.2.1.2. By Treatment Type

8.3.3.2.1.2.1.     By Disease Indication

8.3.3.2.1.2.2.     By Route of Administration

8.3.3.2.1.2.3.     By Therapeutic Class

8.3.3.2.2.             By End User

8.3.4.     Australia Head and Neck Cancer Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type

8.3.4.2.1.1. By Diagnostic Methods

8.3.4.2.1.2. By Treatment Type

8.3.4.2.1.2.1.     By Disease Indication

8.3.4.2.1.2.2.     By Route of Administration

8.3.4.2.1.2.3.     By Therapeutic Class

8.3.4.2.2.             By End User

8.3.5.     South Korea Head and Neck Cancer Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type

8.3.5.2.1.1. By Diagnostic Methods

8.3.5.2.1.2. By Treatment Type

8.3.5.2.1.2.1.     By Disease Indication

8.3.5.2.1.2.2.     By Route of Administration

8.3.5.2.1.2.3.     By Therapeutic Class

8.3.5.2.2.             By End User

8.3.6.     Singapore Head and Neck Cancer Therapeutics Market Outlook

8.3.6.1.         Market Size & Forecast

8.3.6.1.1.             By Value

8.3.6.2.         Market Share & Forecast

8.3.6.2.1.             By Type

8.3.6.2.1.1. By Diagnostic Methods

8.3.6.2.1.2. By Treatment Type

8.3.6.2.1.2.1.     By Disease Indication

8.3.6.2.1.2.2.     By Route of Administration

8.3.6.2.1.2.3.     By Therapeutic Class

8.3.6.2.2.             By End User

9.    South America Head and Neck Cancer Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.1.1.         By Diagnostic Methods

9.2.1.2.         By Treatment Type

9.2.1.2.1.             By Disease Indication

9.2.1.2.2.             By Route of Administration

9.2.1.2.3.             By Therapeutic Class

9.2.1.3.         By End User

9.2.2.     By Country

9.3.  South America: Country Analysis

9.3.1.     Brazil Head and Neck Cancer Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.1.1. By Diagnostic Methods

9.3.1.2.1.2. By Treatment Type

9.3.1.2.1.2.1.     By Disease Indication

9.3.1.2.1.2.2.     By Route of Administration

9.3.1.2.1.2.3.     By Therapeutic Class

9.3.1.2.2.             By End User

9.3.2.     Argentina Head and Neck Cancer Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.1.1. By Diagnostic Methods

9.3.2.2.1.2. By Treatment Type

9.3.2.2.1.2.1.     By Disease Indication

9.3.2.2.1.2.2.     By Route of Administration

9.3.2.2.1.2.3.     By Therapeutic Class

9.3.2.2.2.             By End User

9.3.3.     Colombia Head and Neck Cancer Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.1.1. By Diagnostic Methods

9.3.3.2.1.2. By Treatment Type

9.3.3.2.1.2.1.     By Disease Indication

9.3.3.2.1.2.2.     By Route of Administration

9.3.3.2.1.2.3.     By Therapeutic Class

9.3.3.2.2.             By End User

10.  Middle East and Africa Head and Neck Cancer Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.1.1.      By Diagnostic Methods

10.2.1.2.      By Treatment Type

10.2.1.2.1.           By Disease Indication

10.2.1.2.2.           By Route of Administration

10.2.1.2.3.           By Therapeutic Class

10.2.1.3.      By End User

10.2.2.  By Country

10.3.              MEA: Country Analysis

10.3.1.  South Africa Head and Neck Cancer Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.1.1.               By Diagnostic Methods

10.3.1.2.1.2.               By Treatment Type

10.3.1.2.1.2.1.   By Disease Indication

10.3.1.2.1.2.2.   By Route of Administration

10.3.1.2.1.2.3.   By Therapeutic Class

10.3.1.2.2.           By End User

10.3.2.  Saudi Arabia Head and Neck Cancer Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.1.1.               By Diagnostic Methods

10.3.2.2.1.2.               By Treatment Type

10.3.2.2.1.2.1.   By Disease Indication

10.3.2.2.1.2.2.   By Route of Administration

10.3.2.2.1.2.3.   By Therapeutic Class

10.3.2.2.2.           By End User

10.3.3.  UAE Head and Neck Cancer Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.1.1.               By Diagnostic Methods

10.3.3.2.1.2.               By Treatment Type

10.3.3.2.1.2.1.   By Disease Indication

10.3.3.2.1.2.2.   By Route of Administration

10.3.3.2.1.2.3.   By Therapeutic Class

10.3.3.2.2.           By End User

11.  Clinical Trial Analysis

12.  Impact of COVID-19 on Global Head and Neck Cancer Therapeutics Market

13.  Market Dynamics

13.1.              Drivers

13.2.              Challenges

14.  Market Trends & Developments

15.  Competitive Landscape

15.1.              Competition Outlook

15.2.              Players Profiled

15.2.1.  Eli Lilly and Company

15.2.2.  Bristol Myers Squibb Company

15.2.3.  Sanofi S.A.

15.2.4.  Merck & Co., Inc.

15.2.5.  Pfizer Inc

15.2.6.  AbbVie Inc.

15.2.7.  Bayer AG

15.2.8.  F. Hoffmann-La Roche Ltd.

15.2.9.  Fresenius Medical Care AG & Co. KGaA

15.2.10.                Sun Pharmaceutical Industries Ltd.

15.2.11.                Teva Pharmaceutical Industries Limited

15.2.12.                AstraZeneca Plc.

15.2.13.                Astellas Pharma Inc.

15.2.14.                AB Science SA

15.2.15.                Boston Biomedical, Inc.

16.  Strategic Recommendations

Figures and Tables

List of Figures:

Figure 1: Global Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 2: Global Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 3: Global Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 4: Global Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 5: Global Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 6: Global Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 7: Global Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 8: Global Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 9: Global Head and Neck Cancer Therapeutics Market Share, By Region, By Value, 2017-2027F

Figure 10: Global Head and Neck Cancer Therapeutics Market Share, By Company, By Value, 2021

Figure 11: Global Head and Neck Cancer Therapeutics Market Map, By Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 12: Global Head and Neck Cancer Therapeutics Market Map, By Type, By Diagnostic Methods, Market Size (USD Million) & Growth Rate (%), 2021

Figure 13: Global Head and Neck Cancer Therapeutics Market Map, By Type, By Treatment Type, Market Size (USD Million) & Growth Rate (%), 2021

Figure 14: Global Head and Neck Cancer Therapeutics Market Map, By Treatment Type, By Disease Indication, Market Size (USD Million) & Growth Rate (%), 2021

Figure 15: Global Head and Neck Cancer Therapeutics Market Map, By Treatment Type, By Route of Administration, Market Size (USD Million) & Growth Rate (%), 2021

Figure 16: Global Head and Neck Cancer Therapeutics Market Map, By Treatment Type, By Therapeutic Class, Market Size (USD Million) & Growth Rate (%), 2021

Figure 17: Global Head and Neck Cancer Therapeutics Market Map, By Treatment Type, By End User, Market Size (USD Million) & Growth Rate (%), 2021

Figure 18: Global Head and Neck Cancer Therapeutics Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021

Figure 19: North America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 20: North America Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 21: North America Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 22: North America Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 23: North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 24: North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 25: North America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 26: North America Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 27: North America Head and Neck Cancer Therapeutics Market Share, By Country, By Value, 2017-2027F

Figure 28: United States Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 29: United States Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 30: United States Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 31: United States Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 32: United States Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 33: United States Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 34: United States Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 35: United States Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 36: Canada Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 37: Canada Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 38: Canada Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 39: Canada Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 40: Canada Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 41: Canada Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 42: Canada Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 43: Canada Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 44: Mexico Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 45: Mexico Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 46: Mexico Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 47: Mexico Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 48: Mexico Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 49: Mexico Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 50: Mexico Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 51: Mexico Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 52: Europe Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 53: Europe Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 54: Europe Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 55: Europe Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 56: Europe Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 57: Europe Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 58: Europe Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 59: Europe Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 60: Europe Head and Neck Cancer Therapeutics Market Share, By Country, By Value, 2017-2027F

Figure 61: France Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 62: France Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 63: France Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 64: France Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 65: France Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 66: France Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 67: France Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 68: France Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 69: Germany Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 70: Germany Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 71: Germany Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 72: Germany Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 73: Germany Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 74: Germany Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 75: Germany Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 76: Germany Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 77: United Kingdom Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 78: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 79: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 80: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 81: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 82: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 83: United Kingdom Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 84: United Kingdom Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 85: Italy Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 86: Italy Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 87: Italy Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 88: Italy Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 89: Italy Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 90: Italy Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 91: Italy Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 92: Italy Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 93: Spain Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 94: Spain Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 95: Spain Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 96: Spain Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 97: Spain Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 98: Spain Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 99: Spain Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 100: Spain Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 101: Asia Pacific Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 102: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 103: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 104: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 105: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 106: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 107: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 108: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 109: Asia Pacific Head and Neck Cancer Therapeutics Market Share, By Country, By Value, 2017-2027F

Figure 110: China Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 111: China Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 112: China Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 113: China Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 114: China Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 115: China Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 116: China Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 117: China Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 118: India Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 119: India Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 120: India Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 121: India Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 122: India Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 123: India Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 124: India Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 125: India Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 126: Japan Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 127: Japan Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 128: Japan Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 129: Japan Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 130: Japan Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 131: Japan Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 132: Japan Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 133: Japan Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 134: Australia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 135: Australia Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 136: Australia Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 137: Australia Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 138: Australia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 139: Australia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 140: Australia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 141: Australia Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 142: South Korea Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 143: South Korea Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 144: South Korea Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 145: South Korea Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 146: South Korea Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 147: South Korea Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 148: South Korea Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 149: South Korea Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 150: Singapore Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 151: Singapore Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 152: Singapore Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 153: Singapore Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 154: Singapore Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 155: Singapore Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 156: Singapore Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 157: Singapore Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 158: South America Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 159: South America Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 160: South America Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 161: South America Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 162: South America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 163: South America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 164: South America Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 165: South America Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 166: South America Head and Neck Cancer Therapeutics Market Share, By Country, By Value, 2017-2027F

Figure 167: Brazil Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 168: Brazil Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 169: Brazil Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 170: Brazil Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 171: Brazil Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 172: Brazil Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 173: Brazil Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 174: Brazil Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 175: Argentina Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 176: Argentina Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 177: Argentina Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 178: Argentina Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 179: Argentina Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 180: Argentina Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 181: Argentina Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 182: Argentina Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 183: Colombia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 184: Colombia Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 185: Colombia Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 186: Colombia Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 187: Colombia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 188: Colombia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 189: Colombia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 190: Colombia Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 191: Middle East & Africa Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 192: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 193: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 194: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 195: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 196: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 197: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 198: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 199: Middle East & Africa Head and Neck Cancer Therapeutics Market Share, By Country, By Value, 2017-2027F

Figure 200: South Africa Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 201: South Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 202: South Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 203: South Africa Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 204: South Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 205: South Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 206: South Africa Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 207: South Africa Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 208: Saudi Arabia Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 209: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 210: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 211: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 212: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 213: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 214: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 215: Saudi Arabia Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 216: UAE Head and Neck Cancer Therapeutics Market Size, By Value (USD Million), 2017-2027F

Figure 217: UAE Head and Neck Cancer Therapeutics Market Share, By Type, By Value, 2017-2027F

Figure 218: UAE Head and Neck Cancer Therapeutics Market Share, By Type, By Diagnostic Methods, By Value, 2017-2027F

Figure 219: UAE Head and Neck Cancer Therapeutics Market Share, By Type, By Treatment Type, By Value, 2017-2027F

Figure 220: UAE Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Disease Indication, By Value, 2017-2027F

Figure 221: UAE Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Route of Administration, By Value, 2017-2027F

Figure 222: UAE Head and Neck Cancer Therapeutics Market Share, By Treatment Type, By Therapeutic Class, By Value, 2017-2027F

Figure 223: UAE Head and Neck Cancer Therapeutics Market Share, By End User, By Value, 2017-2027F

Figure 224: Clinical Trials Studies on Head and Neck Cancer Therapeutics, 2017 and 2021

List of Tables:

Table 1: Global Cancer Statistics, 2020

Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020

Table 3: North America Cancer Statistics, 2020

Table 4: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020

Table 5: Europe Cancer Statistics, 2020

Table 6: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020

Table 7: Asia-Pacific Cancer Statistics, 2020

Table 8: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020

Table 9: South America Cancer Statistics, 2020

Table 10: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020

Table 11: Middle East & Africa Cancer Statistics, 2020

Table 12: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020

Table 13: Clinical Trial Studies on Head and Neck Cancer Therapeutics, 2021

Frequently asked questions

down-arrow

The Global Head and Neck Cancer Therapeutics Market is expected to grow at a robust rate of around 7.22% and reach USD3126.26 million in 2027.

down-arrow

The Asia Pacific region is expected to register the highest growth of around 8.18% in the Head and Neck Cancer Therapeutics Market during the forecast period on account of increasing prevalence of different types of head and neck cancers in the region.

down-arrow

Some of the key players operating in the Global Head and Neck Cancer Therapeutics Market include Eli Lilly and Company, Bristol Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Pfizer Inc, AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, AstraZeneca Plc., Astellas Pharma Inc., AB Science SA, Boston Biomedical, Inc., etc.

down-arrow

COVID-19 significantly impacted the growth of Global Head and Neck Cancer Therapeutics Market leading to reluctance among the patients in visiting hospitals. Also, several cancers were shut down and many cancer surgeries were delayed.

profile

Sakshi Bajaal

Business Consultant
Press Release

Head and Neck Cancer Therapeutics Market to Grow with a CAGR of 7.22% until 2027

Mar, 2022

The growing prevalence of different types of head and neck cancers is expected to drive the growth of Global Head and Neck Cancer Therapeutics through 2027